Cartesian Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RNAC research report →
Companyselectabio.com
Selecta Biosciences, Inc. , a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia.
- CEO
- Carsten Brunn
- IPO
- 2016
- Employees
- 66
- HQ
- Watertown, MA, US
Price Chart
Valuation
- Market Cap
- $191.57M
- P/E
- -1.15
- P/S
- 107.93
- P/B
- -1.18
- EV/EBITDA
- -1.26
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -620.96%
- Op Margin
- -5144.51%
- Net Margin
- -8550.65%
- ROE
- 194.13%
- ROIC
- -31.12%
Growth & Income
- Revenue
- $2.80M · -92.81%
- Net Income
- $-130,302,000 · -68.30%
- EPS
- $-5.02 · -67.89%
- Op Income
- $-86,705,000
- FCF YoY
- -142.30%
Performance & Tape
- 52W High
- $15.57
- 52W Low
- $5.60
- 50D MA
- $6.91
- 200D MA
- $8.09
- Beta
- 0.56
- Avg Volume
- 217.00K
Get TickerSpark's AI analysis on RNAC
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 2, 26 | Hoge Elizabeth | other | 758,001 |
| Apr 2, 26 | Hoge Elizabeth | other | 22,740.03 |
| Apr 2, 26 | Kalayoglu Murat | other | 758,001 |
| Apr 2, 26 | Kalayoglu Murat | other | 22,740.03 |
| Mar 13, 26 | Singer Michael | other | 6,555 |
| Jan 6, 26 | Brunn Carsten | sell | 23,766 |
| Jan 6, 26 | Miljkovic Milos | sell | 3,573 |
| Jan 6, 26 | Davis Blaine | sell | 10,591 |
| Jan 2, 26 | DeSilva Nishan M | other | 2,600 |
| Jan 2, 26 | DeSilva Nishan M | other | 7,800 |
Our RNAC Coverage
We haven't published any research on RNAC yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RNAC Report →